chrisvoncsefalvay/vaers-outcomes huggingface dataset:
rash started to lighten up and developed a dark red line around rash; arm was sore where she received the shot; soft lump an inch away from injection site; rash on arm at injection site 4 inches long; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE MASS (soft lump an inch away from injection site), VACCINATION SITE RASH (rash on arm at injection site 4 inches long), VACCINATION SITE ERYTHEMA (rash started to lighten up and developed a dark red line around rash) and VACCINATION SITE PAIN (arm was sore where she received the shot) in a 74-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012LD00A) for COVID-19 vaccination.     No Medical History information was reported.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) at an unspecified dose. On 20-Jan-2021, the patient experienced VACCINATION SITE MASS (soft lump an inch away from injection site), VACCINATION SITE RASH (rash on arm at injection site 4 inches long) and VACCINATION SITE PAIN (arm was sore where she received the shot). On 31-Jan-2021, the patient experienced VACCINATION SITE ERYTHEMA (rash started to lighten up and developed a dark red line around rash). On 01-Feb-2021, VACCINATION SITE ERYTHEMA (rash started to lighten up and developed a dark red line around rash) had resolved. At the time of the report, VACCINATION SITE MASS (soft lump an inch away from injection site) and VACCINATION SITE RASH (rash on arm at injection site 4 inches long) had not resolved and VACCINATION SITE PAIN (arm was sore where she received the shot) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Magnetic resonance imaging: normal (normal) Normal. On an unknown date, Ultrasound scan: normal (normal) Normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant and treatment information not provided.  On the second day her arm was sore where she received the shot. Then she got a red rash on arm at injection site 4 inches long. Concerned that two days after rash, she developed a soft lump an inch away from injection site. Over a couple of weeks, starting yesterday the rash started to lighten up and developed a dark red line around rash. The dark red line went away yesterday, but the rash is back and lump still there.
This is a serious observational study case, initially received from other health professional on 26-Nov-2018, concerns a 39-year-old, adult, female pregnant subject with weight 190 lbs, 64.4 inches, and body mass index (BMI) as 32.2, enrolled in a prospective observational safety study. The subject had two previous pregnancies in which first pregnancy was full term live birth and second pregnancy was elective abortion. The subject had no family history of offspring with major congenital malformation. No relevant maternal and paternal medical history with major congenital malformation. The subject did not use tobacco, alcohol and illicit drugs during pregnancy. The subject's current condition included urinary tract infection (since an unspecified date). Concomitant medications included VITAFOL ONE for healthy pregnancy and MACROBID for urinary tract infection. The subject's last menstrual period date (LMP) was 02-Jun-2018. On 04-Sep-2018, non-invasive prenatal test and first trimester screening test were performed, and no congenital malformations were noted. On 08-Oct-2018, at gestational age of 18-weeks (second trimester of pregnancy) the subject was administered influenza vaccine [batch number: 252232, dose, route of administration, anatomical location, and expiry date: not reported]. On an unspecified date in 2018, after vaccination, the subject developed asthma. At the time of this report, the subject had not recovered from asthma. The subject's estimated delivery date (EDD) was 09-Mar-2019.
little bit of swelling on her nose; glasses making imprint on her face; eyes were puffy; ears felt like when you are on the mountains and you need to pop them; difficulty reading; felt like her pupils were dilated; This spontaneous case was reported by a consumer and describes the occurrence of SWELLING (little bit of swelling on her nose), SKIN SWELLING (glasses making imprint on her face), PERIORBITAL SWELLING (eyes were puffy), EAR DISCOMFORT (ears felt like when you are on the mountains and you need to pop them) and VISION BLURRED (difficulty reading) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for Covid-19 Vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Drug allergy (Severe reaction to Tamiflu).    On 24-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 24-Feb-2021, the patient experienced SWELLING (little bit of swelling on her nose), SKIN SWELLING (glasses making imprint on her face), PERIORBITAL SWELLING (eyes were puffy), EAR DISCOMFORT (ears felt like when you are on the mountains and you need to pop them), VISION BLURRED (difficulty reading) and MYDRIASIS (felt like her pupils were dilated). At the time of the report, SWELLING (little bit of swelling on her nose), SKIN SWELLING (glasses making imprint on her face), PERIORBITAL SWELLING (eyes were puffy), EAR DISCOMFORT (ears felt like when you are on the mountains and you need to pop them), VISION BLURRED (difficulty reading) and MYDRIASIS (felt like her pupils were dilated) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported.  Treatment information was not provided.   This case was linked to US-MODERNATX, INC.-MOD-2021-056424 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-056424:Mother Case MOD21-047898
The pt developed signs and symptoms of increased bruising over 2-3 days. On 8/9/00, PE showed (+) subconjunctival hemorrhage and ecchymosis over trunk, buttocks, arms and legs. Recovery to normal on 8/25/01. No RX given at clinic visit.
SORE KNEE; SORE THUMB; This spontaneous report received from a patient concerned a 60 year old female. The patient's height, and weight were not reported. The patient's past medical history included breast cancer, mastectomy, chemotherapy, and radiation, and concurrent conditions included arthritis, cigarette smoker, abstains from alcohol, and chest tightness, and other pre-existing medical conditions included patient received injection for her arthritis in her back last month. The patient experienced drug allergy when treated with codeine, and paracetamol for drug used for unknown indication. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 12-APR-2021 18:30 for an unspecified indication. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the subject experienced sore knee, and sore thumb. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from sore knee, and sore thumb. This report was non-serious.
This spontaneous report was received from a registered nurse referring to unspecified patients of unknown age and gender. The patients' medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date, the patients received improperly stored doses (5 doses) of PROQUAD lot number L032761, expiration date: 24-FEB-2017 (dose and route of administration were not provided) for prophylaxis. There were no adverse effects reported. Administered doses of PROQUAD were exposed to a temperature excursion of >5°F but <14°F for 2 hours 20 minutes and >14°F but <46°F for 50 minutes. Data logger was involved. There were previous temperature excursions of >14°F but <46°F for 6 hours 10 minutes. This is one of several reports received from the same source. Additional information has been requested. Sender's Comments: US-009507513-1702USA006035.
she is pregnant and received the vaccine; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (she is pregnant and received the vaccine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History was provided by the reporter.     On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. Last menstrual period and estimated date of delivery were not provided. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (she is pregnant and received the vaccine). At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (she is pregnant and received the vaccine) had resolved. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No treatment information was provided.  No concomitant medication was provided.
Patient received a vaccine on 10/13/22 at provider's office during his medical appointment. Patient's daughter forgot about his father receiving a flu vaccine already on 10/13/22. She made an appointment for her father to get a flu shot on 11/22, but showed up on 11/19/22. Consent form was reviewd and signed and initialized by the patient on 11/19/22. Customer received a flu vaccine at the pharmacy on 11/19/22. During billing it was discovered patient received a flu vaccine on 10/13/22. Upon inquiring with patient's daughter she mentioned about her father receiving at provider's office but completely forgot about it.
This case was reported by a physician via call center representative and described the occurrence of headache in a 59-year-old female patient who received SHINGRIX for prophylaxis. On 30th March 2019, the patient received the 2nd dose of SHINGRIX. On 30th March 2019, less than a day after receiving SHINGRIX, the patient experienced headache, general body pain, chills and injection site pain. On 2nd April 2019, the patient experienced rash and blister. On an unknown date, the patient experienced dizziness. On an unknown date, the outcome of the headache, general body pain, dizziness, chills and injection site pain were unknown and the outcome of the rash and blister were not recovered/not resolved. It was unknown if the reporter considered the headache, general body pain, dizziness, chills, injection site pain, rash and blister to be related to SHINGRIX. Additional details were provided as follows: The Physician reported that the patient received the SHINGRIX shot in the left arm and reported to him that she had the normal side effects including headache, body aches and chills with pain at the injection site, however 3 days after receiving vaccination, the patient experienced a rash on her left leg with fine blisters which started in morning the day of reporting. The reporter gave consent to follow up. The reporter reported that GlaxoSmithKline could follow up with the physician directly. However, the reporter did not want to provide any additional details during phone conversation.
This spontaneous report was received from a nurse practitioner referring to an unspecified number of patients of unknown demographics. Information about the patients' pertinent medical history, concurrent conditions and drug reactions/allergies was not reported. On an unknown date, the patients were vaccinated with improperly stored dose of oral, ROTATEQ, lot # K004432 with expiration date 27-JAN-2016, (dose was not provided). Concomitant medication was not reported. No adverse effects reported. Second excursion for oral, ROTATEQ: Temperature/time: 34.7F for 15 minutes. Previous excursion: 34.4F for 30 minutes. This is one of several reports received from the same source. Additional information has been requested.
large raised area on the right arm where injection was given.  Site now warm and itchy as well as slightly red
Headache since day after getting the second shot. Lasted 5 weeks and still ongoing  No issues after first shot
Sore arm; headache; body aches; This spontaneous case was reported by an other health care professional and describes the occurrence of PAIN IN EXTREMITY (Sore arm), HEADACHE (headache) and MYALGIA (body aches) in a 20-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included COVID-19 (patient was diagnosed with Covid-19 twice, before receiving her 1st dose of vaccine). Concurrent medical conditions included Asthma.   On 14-Jun-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 14-Jun-2021, the patient experienced PAIN IN EXTREMITY (Sore arm), HEADACHE (headache) and MYALGIA (body aches). At the time of the report, PAIN IN EXTREMITY (Sore arm), HEADACHE (headache) and MYALGIA (body aches) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were reported   No treatment information was provided   This case was linked to MOD-2021-403245 (Patient Link).
Chest Pain; Bad sweat from head to toe; This spontaneous case was reported by a patient and describes the occurrence of CHEST PAIN (Chest Pain) and HYPERHIDROSIS (Bad sweat from head to toe) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Jan-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced HYPERHIDROSIS (Bad sweat from head to toe). On an unknown date, the patient experienced CHEST PAIN (Chest Pain). At the time of the report, CHEST PAIN (Chest Pain) and HYPERHIDROSIS (Bad sweat from head to toe) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were reported.   No treatment information was provided.
Information has been received from a consumer concerning his 12 year old daughter with no pertinent medical history, allergies or drug reactions who in April 2008, was vaccinated with the second dose GARDASIL vaccine (yeast) 0.5 ml (lot no. not reported). There was no concomitant medication. On an unknown date, the patient developed a bald spot on her head. Therapy with human papillomavirus vaccine was discontinued. The patient's bald spot on head persisted. In Jun 2008 a blood work was done (results not reported). The patient sought unspecified medical attention. No further information is available.
Reported  dizziness initial b/p 92/72 Pulse 80 regular O2 sat 98% Pt given water Afer 15 minutes pt felt better repeat b/p 101/71 monitored for 30 min Pt states she feels comfortable going home No further c/o dizziness
panicking/panics; short winded; Chills; Nausea; little headache; Back ache; This is a spontaneous report received from a contactable consumer (the patient). A 73-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EW0164), via an unspecified route of administration, in right arm on 15Apr2021 at age of 73-year-old at single dose for COVID-19 immunisation. Medical history included high blood pressure diagnosed 12 years ago, diabetes mellitus diagnosed 12 years ago, depression diagnosed 2 years ago, COVID back in Mar2020. The patient's concomitant medications were not reported. The patient previously took the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: ER8732) via an unspecified route of administration, in right arm on 26Mar2021 at age of 73-year-old for COVID-19 immunisation. No other products. The caller was calling about the Pfizer covid shot. The caller had her second dose of the vaccine about an hour ago (15Apr2021). When the caller got home she was okay but currently she was having chills, no fever, nausea, she is having some side effects (15Apr2021). The caller didn't have any allergies. The caller wanted to know if there was something she could drink or if they were going to be there. The caller was short winded but it was easing off. The caller had a back ache and a little headache (15Apr2021). The caller panics a lot too so maybe the panicking was what was causing this. The caller didn't have an allergic reaction that she knows of. The caller wanted to know if this would go away. It seems like it was kind of calming down currently. No investigation assessment. The outcome of events "short winded", "chills", "nausea" was recovering, the outcome of "panicking/panics" was recovered on 15Apr2021, the outcome of other events was unknown.  No follow-up attempts are needed. No further information is expected.
He received the second dose of the vaccine 24 hours ago and now has a headache; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A male patient received bnt162b2 (BNT162B2), administration date 10May2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Past drug history included: Ibuprofen for headache, reaction(s): "drug ineffective"; Acetaminophen for headache, reaction(s): "drug ineffective"; Excedrin for headache; Motrin for headache; Aleve for headache. Vaccination history included: Bnt162b2 (Dose 1), for COVID-19 Immunization. The following information was reported: HEADACHE (non-serious) with onset 11May2021, outcome "unknown", described as "He received the second dose of the vaccine 24 hours ago and now has a headache".  Additional information: Patient wanted to know if he can take any medications for headache and he mentioned that medications like Ibuprofen and acetaminophen were not effective for him. When he had headaches, he preferred to take EXCEDRIN, MOTRIN or ALEVE. Patient wanted to know for how long should he not use these medications. He received the second dose of the vaccine 24 hours ago and now has a headache, he stated that if he does not take his medication the headache does not go away.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Narrative: COVID infection following COVID vaccine series 04/12, Pfizer, dose #1 05/14, Pfizer, dose #2 12/23 COVID swab, result: detected 12/21 pt cc: cough, diarrhea, fatigue, headache, loss of taste or smell, dyspnea exposure: unknown 12/23 ESR: 35 12/23 SARS-COV-2 Variant Sequencing: pending 12/23 pt admit to ED cc: "1 week hx productive cough with brownish phlegm, fever, chills and ST" dx: Acute Viral Syndrome, URI. and COVID with secondary bacterial Bronchitis LOS: 1 day 12/23 CXR impression: No focal consolidation.
Mild headaches in the back of my head. I am not probe to headaches and these started after my vaccination. The headaches are mild and manageable without medication and happen 3-4 times per week for a 10-20 mins at a time.
A few days after receiving my 1st Moderna shot, I looked under my left arm in front of a mirror and noticed a large lump in my armpit. I showed my Primary Doctor who said it should go away and to keep an eye on it. After several weeks it went down to about 1/2 the size. Even today 10/10/21, I still have a noticeable lump under my left arm. After 2nd shot, I developed flu-like symptoms, (fever, chills & body aches) for 24hrs.
"On Friday October 5th around 8:30 am I completed my health screen assessment which included a flu vaccination. A few hours later I started to feel a bit wheezy, however I ignored my feelings then around 2pm that day I had a feeling of shortness of breath which lasted from 60-90 seconds, I continued on with my daily activities and assume it was typical fatigue. Later that evening at around approximately 6pm, I couldn't breathe, my chest tightened up, I felt a sharp throbbing pain in my chest area, which intensified. I felt pressure in my entire upper mid chest area, I couldn't breathe and my heart was pounding and beating rapidly, felt like I was having a mini heart attack. I moved from the chair onto the ground to remove my toddler from my hands, laid on my left side and called out for my husband. The pain, shortness of breathe and  tightening of chest lasted for a few minutes. I remained on the ground until the pain subsided and breathing patterns returned to normal , then remained seated for the next 20 to 30 minutes. Shortly after my breathing returned to normal however my chest still felt tight, abnormal." per employee injury report.
the day following vaccine administration she reported swelling and pain at injection site, diffuse body aches especially neck, shoulders, and back, as well as headache and low grade fever. Symptoms did improve after 24 hrs.
Pain, numbness and muscular spasms in the arm where the vaccine was given  later spreading to the other arm.
During routine monthly inventory in the immunization clinic an expired PPSV23 (pneumovax 23 vaccine) box was discovered.  The box was missing 7 vials.  It is unsure when the vials were used.  They could have been used prior to the expiration date, but that could not be verified.  A report from 9 Jan 2022 to 4 Mar 2022 was pulled and there was 9 doses of PPSV23 given.  The lot numbers as recorded in the EMR matched a valid, unexpired box.  It is possible that expired doses were given, but it is also possible that no expired doses were given.
Pt had flu like symptoms...low grade fever, chills, overall body aches, nausea, and headache. Pt got ZPAK and had flu test which was negative. Pt is feeling fine today 11/9/18.
This case was reported by a other health professional via sales rep and described the occurrence of erythema in a 9-month-old female patient who received PEDIARIX for prophylaxis. In June 2018, the patient received PEDIARIX. On an unknown date, less than a week after receiving PEDIARIX, the patient experienced erythema, petechia and swelling. On an unknown date, the outcome of the erythema, petechia and swelling were unknown. It was unknown if the reporter considered the erythema, petechia and swelling to be related to PEDIARIX. Additional details were reported as follows: The age at vaccination was not reported. The PEDIARIX was administered on approximately 1st June 2018. On 6th June 2018, the redness, swelling, petechiae reported by parents to health care provide. The reporter told that one of their patient experienced unusual red spots on her legs after administration of PEDIARIX vaccine. The parents of the patient were suspecting it could be due to the latex. No additional details were provided.
Extreme swelling of  hands and feel compounded with pain. This further extended to elbows, knees, and left shoulder (injection side). Advised by GP to get second dose I did and things got even worse. Got to the point where I could not lift my arms, or go up and down the stairs. Was told I developed rheumatoid arthritis as a reaction to the shot. Several months later also diagnosed with  Epstein-Barr Virus  reactivation.
My sister suffered a massive stroke with blood clots. Totally paralyzed on right side and limited speech.  Unable to  function on her own,  receiving care at a Nursing  Home
Felt nauseated, dizzy, severe headache, severe stomach ache, fever. Since that time patient developed lupus and problems with her heart.
Urinary frequency and urgency started on June 3 (one day after COVID  injection) and ended  June 8, six days after injection.  Urinalysis showed large amounts of white blood cells which I feel is from inflammation of my bladder and urethra from the COVID vaccine.